Clinical Trials Directory

Trials / Completed

CompletedNCT01295918

Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children

Efficacy of the Probiotic Lactobacillus Reuteri in Prevention of Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children and Adolescents

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
100 (actual)
Sponsor
St Marina University Hospital, Varna, Bulgaria · Academic / Other
Sex
All
Age
3 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if the daily intake of the probiotic Lactobacillus reuteri prevents antibiotic-associated diarrhoea and related Clostridium difficile infections in children and adolescents.

Detailed description

Antibiotic-associated diarrhoea (AAD) occurs in up to 25% of all individuals receiving antibiotics (Bartlett, 2002). In hospitalized patients, AAD is related to significant increases in mortality, length of stay, and cost of medical care (McFarland, 2006). Twenty-nine percent of hospitalized patients may develop diarrhoea after antibiotic use; therefore, identifying strategies to minimize antibiotic-associated diarrhoea could be of significant medical and economic advantage (McFarland, 1998). A promising tool in this area is the probiotic Lactobacillus reuteri

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTL reuteri in children on antibioticsEach patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.

Timeline

Start date
2011-02-01
Primary completion
2013-06-01
Completion
2013-09-01
First posted
2011-02-15
Last updated
2013-09-10

Locations

2 sites across 1 country: Bulgaria

Source: ClinicalTrials.gov record NCT01295918. Inclusion in this directory is not an endorsement.